Godfrey Financial Associates’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

Godfrey Financial Associates’s Portfolio THNR Stock Details THNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.98K	Buy	203 +2	+1%	+$51	﹤0.01%	526
2025 Q4	$5.07K	Buy	+201	New	+$4.94K	﹤0.01%	512

Other funds holding THNR

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Godfrey Financial Associates's THNR Position: Q1 2026 in Review

Godfrey Financial Associates increased its Amplify Weight Loss Drug & Treatment ETF (THNR) stake by 1% in Q1 2026, buying an estimated $51 and bringing the position to 203 shares worth $4.98K. The position accounts for ﹤0.01% of the portfolio, ranked #526.

Godfrey Financial Associates first reported a position in THNR in Q4 2025 and has held it in 2 quarters since. The position peaked at $5.07K in Q4 2025. 4 funds tracked by Wall St. Rank hold THNR as of Q1 2026.

Godfrey Financial Associates held 203 shares of Amplify Weight Loss Drug & Treatment ETF worth $4.98K as of Q1 2026.
Godfrey Financial Associates bought 2 Amplify Weight Loss Drug & Treatment ETF shares in Q1 2026, an estimated $51.
Amplify Weight Loss Drug & Treatment ETF made up ﹤0.01% of Godfrey Financial Associates's portfolio in Q1 2026, its #526 holding.
Godfrey Financial Associates first reported a position in Amplify Weight Loss Drug & Treatment ETF in Q4 2025 and has held it in 2 quarters since.
Godfrey Financial Associates's Amplify Weight Loss Drug & Treatment ETF position peaked at $5.07K in Q4 2025.
4 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q1 2026.

Based on Godfrey Financial Associates's 13F filing for Q1 2026, filed 12 May 2026.